Virtual reality has shown the potential to help patients deal with pain and anxiety during difficult procedures and clinical trials. Clinical Trials Arena speaks to KindVR founder Simon Robertson to...
A new vaccine against malaria, one of the world’s leading causes of child mortality, could...
With supply-chain and shortage issues affecting the global rollout of Covid-19 vaccines, especially for the second dose, researchers are exploring...
The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully...
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals...
Ten countries (populations in excess of 1m) with the highest proportion of people to have received at least one Covid-19 vaccine dose
| Country | Share of population |
|---|---|
| Israel | 62% |
| UAE | 51% |
| UK | 50% |
| US | 43% |
| Chile | 42% |
| Bahrain | 40% |
| Hungary | 40% |
| Uruguay | 33% |
| Canada | 31% |
| Serbia | 29% |
This development is part of CytoDyn’s agreement to collaborate with AEIH to carry out the trials in up to 45…
The global, multi-centre, double-blind, placebo-controlled trial will analyse a single dose of ADG20 administered intramuscularly in two independent cohorts, post-exposure…
Named Medidata Adjudicate, the new digital solution is designed to track all clinical events from start to finish. It helps…
The responses were observed against the SARS-CoV-2 virus and two variants of concern, the B.1.351 variant, which was first detected…
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform that harnesses social media influencers...
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical...
The Covid-19 pandemic has transformed clinical development. Rather than taking ten years to bring a drug to market, vaccine manufacturers showed a drug can be...
The COVID-19 pandemic has led to a surge in the use of remote patient monitoring (RPM) tools to monitor patients outside the standard healthcare settings.
The COVID-19 pandemic triggered unexpected challenges in the business environment prompting pharmaceutical companies to accelerate the adoption of digital transformation strategies.
The COVID-19 pandemic has led to an increase in investments in digital transformation and emerging technologies to deal with the shift towards remote working and...
© Copyright Verdict Media Limited 2021
Expert Commentary & Analysis
View MoreBharat prepares interim Phase I data for intranasal Covid-19 vaccine; reveal planned this month, investigator says
Bharat Biotech is reviewing interim safety and immunogenicity data from a Phase I trial investigating its intranasal Covid-19 vaccine BBV154, with results planned for release this month, said Dr David…
LoA Update: Ortho’s acne gel has approval likelihood clear by 12 points after positive, second Phase III trial
Ortho Dermatologics’ IDP-126 in moderate-to-severe acne vulgaris saw a 12-point upswing in its Likelihood of Approval (LoA) after positive topline results were reported from a second Phase III trial. Topical…
LoA Update: AstraZeneca/Sanofi’s nirsevimab LoA score rises by 8 points after Phase II/III trial hits primary outcome in RSV
As of 26 April, the likelihood of approval (LoA) score for the RSV antibody respiratory syncytial virus (RSV) drug nirsevimab that is being developed by AstraZeneca and Sanofi climbed up…
Pfizer/BioNTech’s COVID-19 vaccine not expected to require a booster in 6–12 months; variant of concern-specific shot preferred but a third Comirnaty dose likely sufficient, experts say
Despite Pfizer and BioNTech suggesting the need for a COVID-19 booster within 12 months from initial Comirnaty (BNT162b2) vaccination, experts said it was unlikely a third dose would be needed that soon. The high…